Recombinant HIV Env Polypeptides for bnAb Induction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective strategies for inducing the production of broadly neutralizing antibodies (bnAbs) against HIV, particularly due to the low frequency of naive B cells with appropriate affinity for HIV Env and the absence of suitable priming immunogens.
Innovation Solution
Development of immunogenic compositions comprising variant HIV Env gp120 polypeptides, recombinant HIV Env trimers, nanoparticles, and other delivery forms to elicit an immune response that mimics the binding properties of the BG18 broadly neutralizing antibody.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional vaccination methods are used, then general immune response is elicited, but broadly neutralizing antibodies with long HCDR3 loops are not induced
Solution Approach 1:
The patent applies preliminary action by designing immunogens that pre-configure the antigenic structure to match the target epitope geometry, thereby preparing the immune system in advance to recognize and bind with high affinity. The engineered trimers present conserved epitopes in a predetermined spatial arrangement that facilitates initial recognition by low-affinity naive B cells, enabling subsequent affinity maturation to produce long-HCDR3 bnAbs.
Solution Approach 2:
The patent employs parameter changes by systematically modifying immunogen parameters including glycan composition, loop lengths, and epitope accessibility to optimize B cell recognition. Specific mutations in the Env protein sequence alter the physical-chemical properties of antigenic surfaces, creating enhanced binding interfaces that can engage naive B cell receptors with sufficient affinity to initiate the neutralization response.
2Reliability
If immunogens are designed to engage conserved epitopes, then neutralization potency increases, but the frequency of priming naive B cells remains very low
Solution Approach 1:
The patent applies the nested doll principle by embedding multiple antigenic determinants within a single trimeric structure, where inner epitopes are protected by outer glycans and loops. This hierarchical arrangement allows sequential engagement of B cell receptors at different maturity stages, with outer structures providing initial low-affinity binding and inner conserved epitopes providing high-affinity neutralization upon B cell activation and differentiation.
Solution Approach 2:
The patent uses glycans as intermediary elements that mediate between the immunogen and naive B cells. These carbohydrate structures serve as recognition motifs that can be bound by germline-encoded B cell receptors, acting as a bridge that connects the immunogen to the naive B cell repertoire and facilitates subsequent affinity maturation to target conserved protein epitopes.
3Reliability
If long HCDR3 loops are generated to reach through glycan shield, then conserved epitopes are contacted, but the priming of appropriate naive B cells is hindered
Solution Approach 1:
The patent applies preliminary action by pre-forming the three-dimensional trimeric structure with conserved epitopes exposed in a geometry that matches the target antibody paratope. This predetermined spatial configuration allows naive B cells with germline-encoded receptors to recognize and bind the immunogen without requiring somatic recombination to generate long HCDR3 loops, thereby simplifying the B cell repertoire requirements while still achieving contact with conserved epitopes.
Data Source
AI summary
The present disclosure relates to recombinant HIV Env polypeptides and their use in the treatment and prevention of HIV/AIDS.